Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Scurry

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Biochimica Et Biophysica Acta. Proteins and Proteomics|October 31, 2016
Annexin A2 and alpha actinin 4 expression correlates with metastatic potential of primary endometrial cancerParul Mittal, Manuela Klingler-Hoffmann, Georgia Arentz, et al.
Journal of Gynecologic Oncology|July 23, 2019
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey Sei Kok, Philip Beale, Rachel L O'Connell, et al.
Proteomics|April 11, 2016
Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imagingParul Mittal, Manuela Klingler-Hoffmann, Georgia Arentz, et al.
Journal of Lower Genital Tract Disease|September 2, 2025
Interobserver Variation in Vulvar Squamous Cell cancer Depth of Invasion Using Two Measurement MethodsJesse Carroll, Tania Day, Jill Allbritton, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 13, 2017
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian CancerAnthony Bonaventura, Rachel L OʼConnell, Cristina Mapagu, et al.
Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancerViola A Heinzelmann-Schwarz, Margaret Gardiner-Garden, Susan M Henshall, et al.
Gynecologic Oncology|May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Histopathology|August 5, 2025
Use of p53 immunohistochemistry can improve diagnostic agreement for differentiated vulvar intraepithelial neoplasia (dVIN): an international reproducibility studyShatavisha Dasgupta, Anne-Sophie Van Rompuy, Christine Bergeron, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Biochimica Et Biophysica Acta. Proteins and Proteomics|October 31, 2016
Annexin A2 and alpha actinin 4 expression correlates with metastatic potential of primary endometrial cancerParul Mittal, Manuela Klingler-Hoffmann, Georgia Arentz, et al.
Journal of Gynecologic Oncology|July 23, 2019
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey Sei Kok, Philip Beale, Rachel L O'Connell, et al.
Proteomics|April 11, 2016
Lymph node metastasis of primary endometrial cancers: Associated proteins revealed by MALDI imagingParul Mittal, Manuela Klingler-Hoffmann, Georgia Arentz, et al.
Journal of Lower Genital Tract Disease|September 2, 2025
Interobserver Variation in Vulvar Squamous Cell cancer Depth of Invasion Using Two Measurement MethodsJesse Carroll, Tania Day, Jill Allbritton, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 13, 2017
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian CancerAnthony Bonaventura, Rachel L OʼConnell, Cristina Mapagu, et al.
Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancerViola A Heinzelmann-Schwarz, Margaret Gardiner-Garden, Susan M Henshall, et al.
Gynecologic Oncology|May 28, 2019
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903Linda Mileshkin, Richard Edmondson, Rachel L O'Connell, et al.
Histopathology|August 5, 2025
Use of p53 immunohistochemistry can improve diagnostic agreement for differentiated vulvar intraepithelial neoplasia (dVIN): an international reproducibility studyShatavisha Dasgupta, Anne-Sophie Van Rompuy, Christine Bergeron, et al.
Pageof 10